Wednesday, 28 February 2018

AstraZeneca spins off autoimmune drugs into new biotech company

LONDON (Reuters) - AstraZeneca is spinning off six early-stage experimental drugs into a new $250 million standalone biotech company focused on severe autoimmune diseases.


from Reuters: Health News http://ift.tt/2BVjCjl

No comments:

Post a Comment